Novo Nordisk acquires Akero Therapeutics for $5.2B to boost its metabolic disease pipeline with EFX. Check out what this ...
The required controlled access program [3] is now in place in Finland, enabling private clinics such as Terveystalo Ruoholahti, where the first patient was treated, to help patients with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback